CS
BIVV

Credit Suisse’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Credit Suisse’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-140,100
Closed -$7.55M – 4236
2017
Q4 		$7.55M Buy
140,100
+26,710
+24% +$1.46M 0.01% 1469
2017
Q3 		$6.47M Sell
113,390
-341
-0.3% -$20K 0.01% 1564
2017
Q2 		$6.84M Sell
113,731
-85,934
-43% -$4.89M 0.01% 1425
2017
Q1 		$10.9M Buy
+199,665
New +$9.83M 0.01% 1167

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Credit Suisse's BIVV Position: Q1 2018 in Review

Credit Suisse sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 140,100 shares — an estimated $7.55M sold.

Credit Suisse first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $10.9M in Q1 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Credit Suisse reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Credit Suisse sold 140,100 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $7.55M.
  • Credit Suisse first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Credit Suisse's Bioverativ Inc. Common Stock position peaked at $10.9M in Q1 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Credit Suisse's 13F filing for Q1 2018, filed 15 May 2018.